R-CODOX-M/R-IVAC Fails to Establish Superior Efficacy Over DA-EPOCH-R in High-Risk Burkitt Lymphoma (2024)

Treatment with the R-CODOX-M and R-IVAC regimens elicited similar efficacy to dose-adjusted infused DA-EPOCH-R in patients with newly diagnosed, high-risk Burkitt lymphoma.

Treatment with the R-CODOX-M and R-IVAC regimens elicited similar efficacy to dose-adjusted infused DA-EPOCH-R in patients with newly diagnosed, high-risk Burkitt lymphoma, according to results from a phase 3 trial (EUDRACT 2013-004394-27).1 Study authors concluded that DA-EPOCH-R appears to be the preferred regimen for patients with high-risk Burkitt lymphoma without central nervous system (CNS) localization.

Data presented at the 2022 EHA Congress also showed DA-EPOCH-R (etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab [Ritxuan]) was associated with significantly fewer infectious complications, transfusions, and hospitalization nights.

At a median follow-up of 19.1 months (range, 0.03-88.4), the estimated 2-year progression-free survival (PFS) for R-CODOX-M (rituximab [Rituxen] plus cyclophosphamide, doxorubicin, vincristine, and methotrexate) with R-IVAC (rituximab, ifosfamide, etoposide, and high-dose cytarabine) was 76%, compared with 70% for DA-EPOCH-R (P = 0.38). Additionally, the estimated 2-year overall survival (OS) rates were 75% and 76% in the R-CODOX-M/R-IVAC and DA-EPOCH-R arms, respectively (P = .85).

The complete metabolic remission (CMR) rate at the end of treatment was 65% in the R-CODOX-M/R-IVAC compared with 66% in the DA-EPOCH-R arm.

“Due to the slow accrual of the study and the [failure] of another European group to participate, we had to close the trial prematurely, and the data cutoff was April 16, 2022,” lead study author Martine Chamuleau, MD, PhD, an internist-hematologist at Amsterdam University Medical Centers, said in a presentation of the data.

The optimal first-line treatment for Burkitt lymphoma has yet to be defined. Prior data showed R-CODOX-M/R-IVAC elicited a 3-year PFS rate of 74%, compared with 95% for DA-EPOCH-R in a single-center study, and 85% in a multicenter study.

This phase 3 trial aimed to further evaluate the efficacy and safety of the 2 regimens. The study enrolled patients aged from 18 to 75 years old with newly diagnosed Burkitt lymphoma (sporadic and HIV associated). Patients were also required to have high-risk disease defined by lactate dehydrogenase (LDH) greater than or equal to the upper limit of normal (ULN); a World Health Organization (WHO) performance status of at least 2; Ann Arbor stage II or IV disease; or a tumor mass of at least 10 cm.

Key exclusion criteria included endemic or Burkitt lymphoma and CNS involvement.

Investigators randomly assigned patients 1:1 to R-CODOX-M/R-IVAC in arm A or DA-EPOCH-R in arm B. In arm A, patients received R-CODOX-M at 800 mg/m2 of cyclophosphamide on day 1, then 200 mg/m2 on days 2 through 5, 40 mg/m2 of doxorubicin on day 1, 1 mg/m2 of vincristine on day 1 and 5 mg/m2 on day 8, and 375 mg/m2 of rituximab on days 1 and 9.

Methotrexate was given at 3000 mg/m2 for patients 65 years or younger and 1000 mg/m2 for patients older than 65 years.

R-IVAC administration included 60 mg/m2 of etoposide on days 1 through 5 and 375 mg/m2 of rituximab on days 3 and 7. Patients 65 years or younger received 1500 mg/m2 of ifosfamide on days 1 through 5, and 2000 mg/m2 of cytarabine on days 1 and 2. Patients over 65 years were given 1000 mg/m2 of ifosfamide and 1000 mg/m2 of cytarabine on the same schedule.

Hospitalization was required for all therapeutic administrations. Treatment lasted at least 16 weeks when there were no delays.

In arm B, DA-EPOCH-R was given at 375 mg/m2 of rituximab on days 1 and 5, 50 mg/m2 to 124 mg/m2 of continuous etoposide on days 1 through 4, 10 mg/m2 to 25 mg/m2 doxorubicin on days 1 through 4, 0.5 mg/m2 of continuous vincristine on days 1 through 4, and 480 mg/m2 to 1866 mg/m2 of cyclophosphamide on day 5. Dose adjustments depended on neutropenia and thrombocytopenia. Out-patient administration was permitted and treatment duration was at least 18 weeks when there were no delays.

The primary objective of the trial was to demonstrate an improvement in 2-year PFS from 70% with R-CODOX-M/R-IVAC to 85% with DA-EPOCH-R. Secondary end points included overall response rate and OS at 2 years, grade 3 or higher toxicities per Common Terminology Criteria for Adverse Events, and number of hospitalization nights.

The median age of enrolled patients in arm A (n = 43) was 50 years (range, 18-75) vs 56 years (range, 22-74) in arm B (n = 41). The majority of patients were male (86% and 88% in arms A and B, respectively), had Burkitt lymphoma (84% and 85%), had Ann Arbor stage III/IV disease (88% and 93%), had a WHO performance status of 0 to 2 (93% and 88%), had LDH greater than the ULN (71% and 70%), were HIV negative (88% and 90%), and had peripheral blasts lower than 25% (98% and 95%).

Additional data showed that 33 of 43 patients in arm A completed treatment compared with 37 of 41 in arm B. R-CODOX-M/R-IVAC was fully dosed in 92% of cycles. In arm B, the maximum dose levels of 1, 2, 3, and 4 were given in 35%, 19%, 24%, and 22% of patients, respectively.

Regarding safety, investigators recorded 129 adverse effects (AEs) of any grade in arm A compared with 84 AEs of any grade in arm B. Chamuleau said more grade 3 AEs occurred in arm A vs arm B.

Additionally, investigators recorded 30 serious AEs in arm A compared with 28 in arm B. The most common serious AEs in both arms were infections and febrile neutropenia, which were more common with R-CODOX-M/R-IVAC (P = .04).

Patients in arm A received more red blood cell transfusions (P < .01) and platelet transfusions (P < .01). Hospitalizations planned per protocol were higher in the arm A (P < .01), though hospitalizations for AEs were also higher in arm A (P = .01).

Reference

  1. Chamuleau MED, Stenner F, Chitu D, et al. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed high-risk Burkitt lymphoma: first results of a multi-center randomized HOVON/SAKK trial. Presented at: 2022 EHA Congress; June 9-12, 2022; Vienna, Austria. Abstract LB2370
R-CODOX-M/R-IVAC Fails to Establish Superior Efficacy Over DA-EPOCH-R in High-Risk Burkitt Lymphoma (2024)

References

Top Articles
Gordon Ramsay Mashed Potatoes Recipe (Photos + Video) - TheFoodXP
62 Quick & Cozy Winter Recipes
Craigslist Houses For Rent In Denver Colorado
Was ist ein Crawler? | Finde es jetzt raus! | OMT-Lexikon
Ixl Elmoreco.com
1movierulzhd.fun Reviews | scam, legit or safe check | Scamadviser
360 Training Alcohol Final Exam Answers
Comcast Xfinity Outage in Kipton, Ohio
CA Kapil 🇦🇪 Talreja Dubai on LinkedIn: #businessethics #audit #pwc #evergrande #talrejaandtalreja #businesssetup…
Horned Stone Skull Cozy Grove
Bme Flowchart Psu
Belle Delphine Boobs
Velocity. The Revolutionary Way to Measure in Scrum
Dark Chocolate Cherry Vegan Cinnamon Rolls
Jbf Wichita Falls
Publix Super Market At Rainbow Square Shopping Center Dunnellon Photos
Craigslist List Albuquerque: Your Ultimate Guide to Buying, Selling, and Finding Everything - First Republic Craigslist
Indiana Wesleyan Transcripts
Days Until Oct 8
Uconn Health Outlook
Kaitlyn Katsaros Forum
Used Safari Condo Alto R1723 For Sale
Ice Dodo Unblocked 76
Del Amo Fashion Center Map
Globle Answer March 1 2023
Sienna
15 Primewire Alternatives for Viewing Free Streams (2024)
Hesburgh Library Catalog
Die wichtigsten E-Nummern
Vlacs Maestro Login
Stouffville Tribune (Stouffville, ON), March 27, 1947, p. 1
Craigslist/Phx
25Cc To Tbsp
Play 1v1 LOL 66 EZ → UNBLOCKED on 66games.io
Lowell Car Accident Lawyer Kiley Law Group
Lehpiht Shop
Duff Tuff
Evil Dead Rise (2023) | Film, Trailer, Kritik
Andrew Lee Torres
Cocorahs South Dakota
Hkx File Compatibility Check Skyrim/Sse
Shell Gas Stations Prices
Online-Reservierungen - Booqable Vermietungssoftware
Reli Stocktwits
Tom Kha Gai Soup Near Me
Mytmoclaim Tracking
French Linen krijtverf van Annie Sloan
Publix Store 840
Hampton Inn Corbin Ky Bed Bugs
Hkx File Compatibility Check Skyrim/Sse
91 East Freeway Accident Today 2022
Cataz.net Android Movies Apk
Latest Posts
Article information

Author: Wyatt Volkman LLD

Last Updated:

Views: 6125

Rating: 4.6 / 5 (66 voted)

Reviews: 81% of readers found this page helpful

Author information

Name: Wyatt Volkman LLD

Birthday: 1992-02-16

Address: Suite 851 78549 Lubowitz Well, Wardside, TX 98080-8615

Phone: +67618977178100

Job: Manufacturing Director

Hobby: Running, Mountaineering, Inline skating, Writing, Baton twirling, Computer programming, Stone skipping

Introduction: My name is Wyatt Volkman LLD, I am a handsome, rich, comfortable, lively, zealous, graceful, gifted person who loves writing and wants to share my knowledge and understanding with you.